Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SR 49059

Known as: SR-49059, SR49059 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

relcovaptan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia
Significance In this study, we show that a primitive brain hormone, arginine vasopressin (AVP), which has hitherto been… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor
The neuropeptides oxytocin (OT) and vasopressin (AVP) are recognized for their modulation of social processes in humans when… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Increased vasopressin transmission from the paraventricular nucleus to the rostral medulla augments cardiorespiratory outflow in chronic intermittent hypoxia-conditioned rats.
A co-morbidity of sleep apnoea is hypertension associated with elevated sympathetic nerve activity (SNA) which may result from… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
The mechanisms by which arginine vasopressin (AVP) exerts its antidiuretic and pressor effects, via activation of V2 and V1a… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors*
Some membrane-permeable antagonists restore cell surface expression of misfolded receptors retained in the endoplasmic reticulum… Expand
Is this relevant?
2004
2004
Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway.
Malignant growth of small-cell lung carcinoma is promoted by various neuroendocrine autocrine/paracrine loops. Therefore, to… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
Vasopressin receptor subtype(s) responsible for stimulation of insulin release from pancreatic beta cells were investigated by… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
2003
2003
Vasopressin Differentially Modulates Non-NMDA Receptors in Vasopressin and Oxytocin Neurons in the Supraoptic Nucleus
Magnocellular neurons of the supraoptic nucleus release the neuropeptides oxytocin and vasopressin from their dendrites to… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model.
BACKGROUND AND PURPOSE Cerebral edema develops very early after the onset of focal cerebral ischemia and may be a major factor in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
1993
1993
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
SR 49059, a new potent and selective orally active, nonpeptide vasopressin (AVP) antagonist has been characterized in several in… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE